Cargando…

Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A

BACKGROUND: Toll-like receptor (TLR)4 agonists are known potent immunostimulatory compounds. These compounds can be formulated as part of novel adjuvants to enhance vaccine medicated immune responses. However, the contribution of the formulation to the innate in vivo activity of TLR4 agonist compoun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lambert, Stacie L., Yang, Chin-Fen, Liu, Zheng, Sweetwood, Rosemary, Zhao, Jackie, Cheng, Lily, Jin, Hong, Woo, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532059/ https://www.ncbi.nlm.nih.gov/pubmed/23284726 http://dx.doi.org/10.1371/journal.pone.0051618

Ejemplares similares

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012)

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
por: Coler, Rhea N., et al.
Publicado: (2011)

A Novel Respiratory Syncytial Virus (RSV) F Subunit Vaccine Adjuvanted with GLA-SE Elicits Robust Protective T(H)1-Type Humoral and Cellular Immunity In Rodent Models
por: Lambert, Stacie L., et al.
Publicado: (2015)

Schistosoma mansoni antigen Sm-p80: prophylactic efficacy using TLR4 agonist vaccine adjuvant glucopyranosyl lipid A-Alum in murine and non-human primate models
por: Zhang, Weidong, et al.
Publicado: (2018)

Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A
por: Lu, Hailing, et al.
Publicado: (2020)

Glucopyranosyl Lipid A Adjuvant Significantly Enhances HIV Specific T and B Cell Responses Elicited by a DNA-MVA-Protein Vaccine Regimen
por: McKay, Paul F., et al.
Publicado: (2014)

TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
por: Luchner, Marina, et al.
Publicado: (2021)

Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants
por: Strobl, Sebastian, et al.
Publicado: (2022)

A novel defined TLR3 agonist as an effective vaccine adjuvant
por: Ko, Kwang Hyun, et al.
Publicado: (2023)

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial
por: Joachim, Agricola, et al.
Publicado: (2016)

Small Cationic DDA:TDB Liposomes as Protein Vaccine Adjuvants Obviate the Need for TLR Agonists in Inducing Cellular and Humoral Responses
por: Milicic, Anita, et al.
Publicado: (2012)

Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans
por: Anderson, Jenna, et al.
Publicado: (2018)

BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
por: Kaushik, Deepender, et al.
Publicado: (2020)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

First Total Synthesis of 5′-O-α-d-Glucopyranosyl Tubercidin
por: Ouyang, Wenliang, et al.
Publicado: (2020)

RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine
por: Jangra, Sonia, et al.
Publicado: (2022)

Differential Adjuvant Activities of TLR7 and TLR9 Agonists Inversely Correlate with Nitric Oxide and PGE(2) Production
por: Lee, Jinhee, et al.
Publicado: (2015)

Using distinct molecular signatures of human monocytes and dendritic cells to predict adjuvant activity and pyrogenicity of TLR agonists
por: Kamgang, Richard Kenmoe, et al.
Publicado: (2008)

Anomeric Spironucleosides of β-d-Glucopyranosyl Uracil as Potential Inhibitors of Glycogen Phosphorylase
por: Stathi, Aggeliki, et al.
Publicado: (2019)

The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
por: Demaria, Sandra, et al.
Publicado: (2013)

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice
por: Buffa, Viviana, et al.
Publicado: (2012)

Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants
por: Shanmugam, Arulkumaran, et al.
Publicado: (2012)

Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics
por: Adanitsch, Florian, et al.
Publicado: (2018)

High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation
por: Gadd, Adam J.R., et al.
Publicado: (2018)

TLR4 Agonist Monophosphoryl Lipid A Alleviated Radiation-Induced Intestinal Injury
por: Guo, Jiaming, et al.
Publicado: (2019)

2-O-α-D-Glucopyranosyl-l-ascorbic acid as an antitumor agent for infusion therapy
por: Miura, Kaori, et al.
Publicado: (2017)

Straightforward Synthesis of Novel 1-(2′-α-O-D-Glucopyranosyl ethyl) 2-Arylbenzimidazoles
por: Arumugam, Natarajan, et al.
Publicado: (2012)

An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants
por: Kayesh, Mohammad Enamul Hoque, et al.
Publicado: (2021)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses
por: Gutjahr, Alice, et al.
Publicado: (2020)

New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants
por: Romerio, Alessio, et al.
Publicado: (2023)

Baseline immune profile by CyTOF can predict response to an investigational adjuvanted vaccine in elderly adults
por: Lingblom, Christine M. D., et al.
Publicado: (2018)

Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)

Physicochemical characterization of biological and synthetic forms of two lipid A-based TLR4 agonists
por: Hu, Gang, et al.
Publicado: (2023)

Synthesis of New Series of 2-C-(β-D-glucopyranosyl)-Pyrimidines and Their Evaluation as Inhibitors of Some Glycoenzymes
por: Szennyes, Eszter, et al.
Publicado: (2020)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine
por: Zhou, Shi-Hao, et al.
Publicado: (2022)

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination
por: Dowling, David J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j12iu3l2eit23hdeldq8ud25dg